シクロスポリンの世界市場レポート 2025年

シクロスポリン市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.3％で49億6,000万米ドルに成長します。予測期間における成長の背景には、臓器提供の増加、免疫療法の採用拡大、高齢者人口の増加、特殊医薬品市場の拡大、関節リウマチの罹患率の増加などがあります。予測期間における主な動向としては、新たな免疫抑制療法の開発、AIを活用した創薬の進展、ナノテクノロジーの統合、医薬品サプライチェーンにおけるブロックチェーン技術の活用、ドラッグデリバリーシステムの革新などが挙げられます。

自己免疫疾患の罹患率の増加は、シクロスポリン市場の成長を大きく促進すると予想されます。自己免疫疾患は、免疫系が誤って身体自身の組織を攻撃することで炎症、臓器障害、慢性的な状態を引き起こすことが特徴です。その要因として、遺伝的素因や遺伝子診断の進歩が挙げられ、よりリスクの高い個人を特定できるようになってきています。強力な免疫抑制剤であるシクロスポリンは、T細胞の活性化を阻害し、過剰な免疫反応を緩和することにより、関節リウマチ、ループス、乾癬などの自己免疫疾患の治療に広く使用されています。例えば、2024年5月、米国国立衛生研究所（NIH）は、2022年の乾癬性関節炎（PsA）の有病率は0.221％で、10万人当たりの発症率は13.54であると報告しました。このような疾病率の上昇はシクロスポリンに対する需要の増加を生み出し、自己免疫疾患管理におけるシクロスポリンの重要な役割を強調しています。

シクロスポリン市場の企業は、製品の信頼性を高め、市場に参入するために、規制当局の承認取得にますます注力しています。規制当局の承認は、製品の安全性と治療効果を確認し、より広範な採用を可能にし、利害関係者の信頼を強化します。例えば、2023年6月、ドイツを拠点とするバイオ医薬品会社Novaliq GmbHは、VEVYE（シクロスポリン点眼液）0.1％の米国FDA承認を取得しました。本製品は、ドライアイ治療薬として承認された初の水不使用のシクロスポリン点眼液であり、使用後4週間で有効性が実証されました。VEVYEは、防腐剤、油分、界面活性剤を使用することなく、バイオアベイラビリティと眼表面滞留性を高める新しい水不含製剤であるEyeSol技術を活用しています。カルシニューリン阻害剤として、DEDに伴う炎症を抑え、眼科領域における差別化された治療選択肢を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界シクロスポリンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のシクロスポリン市場：成長率分析
• 世界のシクロスポリン市場の実績：規模と成長, 2019-2024
• 世界のシクロスポリン市場の予測：規模と成長, 2024-2029, 2034F
• 世界シクロスポリン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のシクロスポリン市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 移植拒絶反応予防
• 関節リウマチ
• 乾癬
• 自己免疫性重症筋無力症
• ドライアイ
• その他の適応症
• 世界のシクロスポリン市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• カプセル
• 目薬
• 液体ソリューション
• クリームと軟膏
• 世界のシクロスポリン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• トピック
• 非経口
• 世界のシクロスポリン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のシクロスポリン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界のシクロスポリン市場移植拒絶反応予防の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腎臓移植
• 肝臓移植
• 心臓移植
• 肺移植
• その他の移植
• 世界のシクロスポリン市場関節リウマチの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 中等度の関節リウマチ
• 重度の関節リウマチ
• 世界のシクロスポリン市場乾癬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尋常性乾癬
• 紅皮症性乾癬
• 滴状乾癬
• 膿疱性乾癬
• 世界のシクロスポリン市場自己免疫性重症筋無力症の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性ドライアイ
• 重度のドライアイ
• 世界のシクロスポリン市場ドライアイの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性ドライアイ
• 重度のドライアイ
• 世界のシクロスポリン市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• アトピー性皮膚炎
• ぶどう膜炎
• ネフローゼ症候群
• 炎症性腸疾患（IBD）

第7章 地域別・国別分析

• 世界のシクロスポリン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のシクロスポリン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• シクロスポリン市場：競合情勢
• シクロスポリン市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Apotex Inc.
• Cipla Ltd
• Dr. Reddy's Laboratories Ltd
• Lupin Limited
• Glenmark Pharmaceuticals Ltd
• Taj Pharmaceuticals Limited
• Panacea Biotec Ltd
• Novaliq GmbH
• Simson Pharma Limited
• Strides Pharma Science Ltd
• AdvaCare Pharma
• JoinHub Pharma
• Grevis Pharmaceuticals Pvt Ltd
• GMT Pharma International
• Logos Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• シクロスポリン市場2029：新たな機会を提供する国
• シクロスポリン市場2029：新たな機会を提供するセグメント
• シクロスポリン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cyclosporine is an immunosuppressive drug mainly used to prevent organ transplant rejection and to manage specific autoimmune diseases. It functions by inhibiting T-cell activity through suppression of the enzyme calcineurin, effectively reducing inflammation and immune system responses. Additionally, cyclosporine is utilized in ophthalmic formulations to treat eye conditions such as dry eye disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for cyclosporine include transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and others. Transplant rejection prophylaxis refers to the use of cyclosporine in preventing the immune system from rejecting transplanted organs, such as the kidney, liver, or heart. Cyclosporine is available in several dosage forms, including capsules, eye drops, liquid solutions, creams, and ointments, and is administered through oral, topical, and parenteral routes. It is distributed via hospital pharmacies, retail pharmacies, and online pharmacies and is used by various end users, including hospitals, homecare settings, specialty centers, and others.

The cyclosporine market research report is one of a series of new reports from The Business Research Company that provides cyclosporine market statistics, including cyclosporine industry global market size, regional shares, competitors with a cyclosporine market share, detailed cyclosporine market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine industry. This cyclosporine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cyclosporine market size has grown rapidly in recent years. It will grow from$2.65 billion in 2024 to $3.01 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth during the historic period can be attributed to an increasing number of organ transplants, a rise in autoimmune disease cases, a growing prevalence of chronic illnesses, a surge in kidney-related disorders, and the expansion of transplant centers.

The cyclosporine market size is expected to see rapid growth in the next few years. It will grow to$4.96 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing organ donations, growing adoption of immunotherapy, a rising population of geriatric patients, an expanding market for specialty pharmaceuticals, and a higher incidence of rheumatoid arthritis. Major trends in the forecast period include the development of new immunosuppressive therapies, advancements in AI-driven drug discovery, integration of nanotechnology, the use of blockchain technology in the drug supply chain, and innovations in drug delivery systems.

The increasing incidence of autoimmune diseases is expected to significantly drive growth in the cyclosporine market. Autoimmune diseases are characterized by the immune system mistakenly attacking the body's own tissues, resulting in inflammation, organ damage, and chronic conditions. Contributing factors include genetic predisposition and advancements in genetic diagnostics, which have led to better identification of individuals at higher risk. Cyclosporine, a potent immunosuppressant, is widely used to treat autoimmune diseases such as rheumatoid arthritis, lupus, and psoriasis by inhibiting T-cell activation and moderating excessive immune responses. For example, in May 2024, the National Institutes of Health (NIH) reported that the prevalence of psoriatic arthritis (PsA) in 2022 was 0.221%, with an incidence rate of 13.54 per 100,000 individuals. These rising disease rates are generating increased demand for cyclosporine, underscoring its vital role in autoimmune disease management.

Companies within the cyclosporine market are increasingly focused on achieving regulatory approvals to enhance product credibility and market reach. Regulatory endorsement affirms a product's safety and therapeutic efficacy, enabling broader adoption and strengthening stakeholder confidence. For instance, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical firm, received U.S. FDA approval for VEVYE (cyclosporine ophthalmic solution) 0.1%. This product is the first water-free cyclosporine solution approved for the treatment of dry eye disease (DED), demonstrating effectiveness within four weeks of use. VEVYE leverages EyeSol technology, a novel water-free formulation that enhances bioavailability and ocular surface retention without using preservatives, oils, or surfactants. As a calcineurin inhibitor, it reduces inflammation associated with DED, offering a differentiated treatment option in the ophthalmic segment.

In July 2024, Lupin Limited, an India-based pharmaceutical company, announced a strategic partnership with Huons Co. Ltd. to launch a cyclosporine ophthalmic nanoemulsion in Mexico. The collaboration aims to commercialize this advanced formulation for treating dry eye syndrome and ocular inflammation, thereby expanding Lupin's ophthalmic product offerings and reinforcing its presence in Latin America. Huons Co. Ltd., a South Korea-based pharmaceutical innovator, specializes in developing and commercializing ophthalmic therapies, including advanced cyclosporine-based formulations. This partnership reflects ongoing efforts in the industry to address unmet needs in eye care through cross-border collaboration and innovation.

Major players in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, and Logos Pharma.

Asia-Pacific was the largest region in the cyclosporine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in cyclosporine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cyclosporine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cyclosporine market consists of sales of injectable cyclosporine, ophthalmic formulations, intravenous solutions, topical formulations, and oral solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cyclosporine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cyclosporine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cyclosporine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cyclosporine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Transplant Rejection Prophylaxis; Rheumatoid Arthritis; Psoriasis; Autoimmune Myasthenia Gravis; Dry Eye; Other Indications
• 2) By Dosage Form: Capsule; Eye Drops; Liquid Solutions; Creams And Ointments
• 3) By Route Of Administration: Oral; Topical; Parenteral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-Users: Hospitals; Homecare; Speciality Centres; Other End-Users
• Subsegments:
• 1) By Transplant Rejection Prophylaxis: Kidney Transplant; Liver Transplant; Heart Transplant; Lung Transplant; Other Transplants
• 2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis; Severe Rheumatoid Arthritis
• 3) By Psoriasis: Plaque Psoriasis; Erythrodermic Psoriasis; Guttate Psoriasis; Pustular Psoriasis
• 4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis; Ocular Myasthenia Gravis
• 5) By Dry Eye: Chronic Dry Eye; Severe Dry Eye
• 6) By Other Indications: Atopic Dermatitis; Uveitis; Nephrotic Syndrome; Inflammatory Bowel Disease (IBD)
• Companies Mentioned: Novartis AG; Viatris Inc.; Teva Pharmaceutical Industries Ltd; Sandoz International GmbH; Sun Pharmaceutical Industries Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cyclosporine Market Characteristics

3. Cyclosporine Market Trends And Strategies

4. Cyclosporine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cyclosporine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cyclosporine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cyclosporine Market Growth Rate Analysis
• 5.4. Global Cyclosporine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cyclosporine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cyclosporine Total Addressable Market (TAM)

6. Cyclosporine Market Segmentation

• 6.1. Global Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transplant Rejection Prophylaxis
• Rheumatoid Arthritis
• Psoriasis
• Autoimmune Myasthenia Gravis
• Dry Eye
• Other Indications
• 6.2. Global Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsule
• Eye Drops
• Liquid Solutions
• Creams And Ointments
• 6.3. Global Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Topical
• Parenteral
• 6.4. Global Cyclosporine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Cyclosporine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Speciality Centres
• Other End-Users
• 6.6. Global Cyclosporine Market, Sub-Segmentation Of Transplant Rejection Prophylaxis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Kidney Transplant
• Liver Transplant
• Heart Transplant
• Lung Transplant
• Other Transplants
• 6.7. Global Cyclosporine Market, Sub-Segmentation Of Rheumatoid Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Moderate Rheumatoid Arthritis
• Severe Rheumatoid Arthritis
• 6.8. Global Cyclosporine Market, Sub-Segmentation Of Psoriasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plaque Psoriasis
• Erythrodermic Psoriasis
• Guttate Psoriasis
• Pustular Psoriasis
• 6.9. Global Cyclosporine Market, Sub-Segmentation Of Autoimmune Myasthenia Gravis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Dry Eye
• Severe Dry Eye
• 6.10. Global Cyclosporine Market, Sub-Segmentation Of Dry Eye, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Dry Eye
• Severe Dry Eye
• 6.11. Global Cyclosporine Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atopic Dermatitis
• Uveitis
• Nephrotic Syndrome
• Inflammatory Bowel Disease (IBD)

7. Cyclosporine Market Regional And Country Analysis

• 7.1. Global Cyclosporine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cyclosporine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cyclosporine Market

• 8.1. Asia-Pacific Cyclosporine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cyclosporine Market

• 9.1. China Cyclosporine Market Overview
• 9.2. China Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cyclosporine Market

• 10.1. India Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cyclosporine Market

• 11.1. Japan Cyclosporine Market Overview
• 11.2. Japan Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cyclosporine Market

• 12.1. Australia Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cyclosporine Market

• 13.1. Indonesia Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cyclosporine Market

• 14.1. South Korea Cyclosporine Market Overview
• 14.2. South Korea Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cyclosporine Market

• 15.1. Western Europe Cyclosporine Market Overview
• 15.2. Western Europe Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cyclosporine Market

• 16.1. UK Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cyclosporine Market

• 17.1. Germany Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cyclosporine Market

• 18.1. France Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cyclosporine Market

• 19.1. Italy Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cyclosporine Market

• 20.1. Spain Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cyclosporine Market

• 21.1. Eastern Europe Cyclosporine Market Overview
• 21.2. Eastern Europe Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cyclosporine Market

• 22.1. Russia Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cyclosporine Market

• 23.1. North America Cyclosporine Market Overview
• 23.2. North America Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cyclosporine Market

• 24.1. USA Cyclosporine Market Overview
• 24.2. USA Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cyclosporine Market

• 25.1. Canada Cyclosporine Market Overview
• 25.2. Canada Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cyclosporine Market

• 26.1. South America Cyclosporine Market Overview
• 26.2. South America Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cyclosporine Market

• 27.1. Brazil Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cyclosporine Market

• 28.1. Middle East Cyclosporine Market Overview
• 28.2. Middle East Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cyclosporine Market

• 29.1. Africa Cyclosporine Market Overview
• 29.2. Africa Cyclosporine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cyclosporine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cyclosporine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cyclosporine Market Competitive Landscape And Company Profiles

• 30.1. Cyclosporine Market Competitive Landscape
• 30.2. Cyclosporine Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sandoz International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Cyclosporine Market Other Major And Innovative Companies

• 31.1. Apotex Inc.
• 31.2. Cipla Ltd
• 31.3. Dr. Reddy's Laboratories Ltd
• 31.4. Lupin Limited
• 31.5. Glenmark Pharmaceuticals Ltd
• 31.6. Taj Pharmaceuticals Limited
• 31.7. Panacea Biotec Ltd
• 31.8. Novaliq GmbH
• 31.9. Simson Pharma Limited
• 31.10. Strides Pharma Science Ltd
• 31.11. AdvaCare Pharma
• 31.12. JoinHub Pharma
• 31.13. Grevis Pharmaceuticals Pvt Ltd
• 31.14. GMT Pharma International
• 31.15. Logos Pharma

32. Global Cyclosporine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cyclosporine Market

34. Recent Developments In The Cyclosporine Market

35. Cyclosporine Market High Potential Countries, Segments and Strategies

• 35.1 Cyclosporine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cyclosporine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cyclosporine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34812_Cyclosporine_GMR_2025